These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24421250)

  • 21. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation.
    Haunstrup LM; Ebbesen LH; Hansen M; Severinsen MT; Aggerholm A
    Exp Hematol; 2018 Dec; 68():62-65. PubMed ID: 30292681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT; Tyner JW; Gotlib J
    Curr Hematol Malig Rep; 2017 Oct; 12(5):432-441. PubMed ID: 28983816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia.
    Duployez N; Willekens C; Plo I; Marceau-Renaut A; de Botton S; Fenwarth L; Boyer T; Huet G; Nibourel O; Rose C; Nelken B; Quesnel B; Preudhomme C
    Blood; 2019 Dec; 134(26):2414-2416. PubMed ID: 31697825
    [No Abstract]   [Full Text] [Related]  

  • 25. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
    Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
    Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current strategies in the diagnosis and management of chronic neutrophilic leukemia.
    Otgonbat A; Zhao M
    Chin Med J (Engl); 2014; 127(24):4258-62. PubMed ID: 25533830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomics of chronic neutrophilic leukemia.
    Maxson JE; Tyner JW
    Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
    Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
    Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetically informed therapy in leukemia.
    Radich J
    N Engl J Med; 2013 May; 368(19):1838-9. PubMed ID: 23656651
    [No Abstract]   [Full Text] [Related]  

  • 31. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent
    Gunawan AS; McLornan DP; Wilkins B; Waghorn K; Hoade Y; Cross NCP; Harrison CN
    Haematologica; 2017 Jun; 102(6):e238-e240. PubMed ID: 28302714
    [No Abstract]   [Full Text] [Related]  

  • 32. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.
    Maxson JE; Luty SB; MacManiman JD; Abel ML; Druker BJ; Tyner JW
    J Biol Chem; 2014 Feb; 289(9):5820-7. PubMed ID: 24403076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
    Mc Lornan DP; Percy MJ; Jones AV; Cross NC; Mc Mullin MF
    Haematologica; 2005 Dec; 90(12):1696-7. PubMed ID: 16330446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
    Stahl M; Xu ML; Steensma DP; Rampal R; Much M; Zeidan AM
    Ann Hematol; 2016 Jun; 95(7):1197-200. PubMed ID: 27068405
    [No Abstract]   [Full Text] [Related]  

  • 35. [Chronic neutrophilic leukemia with CSF3R mutation and concurrent multiple myeloma: one case report].
    He M; Zhao XC; Bai H
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1052. PubMed ID: 32023742
    [No Abstract]   [Full Text] [Related]  

  • 36. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.
    Lasho TL; Mims A; Elliott MA; Finke C; Pardanani A; Tefferi A
    Leukemia; 2014 Jun; 28(6):1363-5. PubMed ID: 24445868
    [No Abstract]   [Full Text] [Related]  

  • 37. A novel colony stimulating factor 3 receptor activating mutation identified in a patient with chronic neutrophilic leukemia.
    Maniaci BN; Chung J; Sanz-Altamira P; DeAngelo DJ; Maxson JE
    Haematologica; 2023 Jul; 108(7):1945-1950. PubMed ID: 36579444
    [No Abstract]   [Full Text] [Related]  

  • 38. Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm.
    Bernal M; Jiménez P; Puerta J; Ruíz-Cabello F; Jurado M
    Ann Hematol; 2017 Aug; 96(8):1399-1401. PubMed ID: 28516193
    [No Abstract]   [Full Text] [Related]  

  • 39. Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R.
    Touw IP; Beekman R
    Haematologica; 2013 Oct; 98(10):1490-2. PubMed ID: 24091926
    [No Abstract]   [Full Text] [Related]  

  • 40. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
    Zuo Z; Li S; Xu J; You MJ; Khoury JD; Yin CC
    Curr Hematol Malig Rep; 2019 Oct; 14(5):376-385. PubMed ID: 31388824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.